Article Text

PDF
FRI0479 Predictors of long-term modified minimal disease activity response in peripheral spondyloarthritis patients treated with adalimumab
  1. LC Coates1,
  2. S Abraham2,
  3. W Tillett3,
  4. PJ Mease4,
  5. S Ramiro5,
  6. T Wu6,
  7. X Wang6,
  8. AL Pangan6,
  9. I-H Song6
  1. 1University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds
  2. 2NIHR/Wellcome CRF, Imperial College Healthcare NHS Trust, London
  3. 3Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom
  4. 4Swedish Medical Center and University of Washington, Seattle, United States
  5. 5Leiden University Medical Center, Leiden, Netherlands
  6. 6AbbVie Inc., N Chicago, United States

Abstract

Background There is a lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA). Therefore, a modified version of the minimal disease activity (mMDA)1 was developed and validated. Identification of factors that predict long-term mMDA response in pSpA patients (pts) can facilitate decisions regarding treatment initiation and maintenance.

Objectives The purpose of this analysis was to determine predictors of long-term mMDA response following adalimumab (ADA) treatment in pSpA pts from the ABILITY-2 study.

Methods ABILITY-22 was a phase 3 randomized, double-blind trial evaluating the efficacy and safety of 40 mg ADA every other week versus placebo (PBO) over 12 weeks (wks) followed by open-label (OL) ADA for 144 wks in pts with pSpA. This post-hoc analysis included pts who received at least one dose of ADA during the PBO-controlled period or OL extension. The mMDA for pSpA was defined as achieving at least 5 out of the following 6 criteria: 1) TJC78 ≤1; 2) SJC76 ≤1; 3) pt pain visual analog scale (VAS) ≤15 of 100 mm; 4) pt global activity (PtGA) VAS ≤20 of 100 mm; 5) HAQ-DI ≤0.5; and 6) tender entheseal points ≤1 (Leeds Enthesitis Index [LEI] or Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index). In this post hoc analysis, multiple logistic regression with stepwise variable selection was used to determine predictors of long-term (yrs 1–3) and sustained (defined as mMDA for at least 24 consecutive wks) mMDA responses. Variable selection of baseline (BL) pt demographics and disease characteristics were performed with and without mMDA response at wk 16 (mMDA16) as a candidate. In pts achieving mMDA at wk 16, ADA exposure ranged between 4 and 16 wks.

Results In pSpA pts treated with ADA, mMDA (5/6 LEI or SPARCC) was achieved by almost 41%, 49%, and 50% of pts at yrs 1, 2, and 3, respectively and sustained mMDA response was achieved by 42% of pts. Regardless of mMDA definition, achieving mMDA response at wk 16 (up to 16 wks of ADA) was a robust positive predictor of attaining both long-term mMDA at yrs 1–3 and sustained mMDA (Figure). In the model examining the BL predictors (model without mMDA16), age, BL enthesitis and BL BASDAI scores were most commonly selected as negative predictors for achieving long-term and sustained mMDA. Other selected predictors included BL dactylitis, physician's global assessment, hsCRP, and male sex; however, these predictors were not consistently selected for all time points or sustained mMDA.

Conclusions Early mMDA response is a stronger and more consistent predictor of long-term mMDA, whether at 1, 2, or 3 yrs or sustained over time, than BL characteristics. The 5/6 versions of mMDA could be an appropriate treatment target in pSpA pts.

References

  1. Coates LC, et al., Ann Rheum Dis, 2016; 75:334.

  2. Mease PJ, et al., Arthritis Rheumatol, 2015; 67(4): p.914–23.

References

Acknowledgements AbbVie funded the study (NCT01064856), contributed to its design, and participated in data collection, analysis and interpretation of the data, and in writing, review, and approval of the publication. Medical writing support was provided by Deepa Venkitaramani, PhD, of AbbVie.

Disclosure of Interest L. Coates Grant/research support from: AbbVie, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sun Pharma, and UCB, Consultant for: AbbVie, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sun Pharma, and UCB, Speakers bureau: AbbVie, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sun Pharma, and UCB, S. Abraham Grant/research support from: AbbVie, Celgene, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Celgene, Novartis, Pfizer, and UCB, Speakers bureau: AbbVie, Celgene, Novartis, Pfizer, and UCB, W. Tillett Grant/research support from: AbbVie, Celgene, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Celgene, Novartis, Pfizer, and UCB, Speakers bureau: AbbVie, Celgene, Novartis, Pfizer, and UCB, P. Mease Grant/research support from: AbbVie, Amgen, Bristol Myers, Celgene, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, Sun Pharma, and UCB, Consultant for: AbbVie, Amgen, Bristol Myers, Celgene, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, Sun Pharma, and UCB, Speakers bureau: AbbVie, Amgen, Bristol Myers, Celgene, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, Sun Pharma, and UCB, S. Ramiro: None declared, T. Wu Shareholder of: AbbVie, Employee of: AbbVie, X. Wang Shareholder of: AbbVie, Employee of: AbbVie, A. Pangan Shareholder of: AbbVie, Employee of: AbbVie, I.-H. Song Shareholder of: AbbVie, Employee of: AbbVie

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.